NCT04160312 (NOURISH) is a NA clinical trial of Mitopure™ (Proprietary Urolithin A) in Healthy, sponsored by Amazentis SA.

Who is sponsoring NCT04160312?

NCT04160312 is sponsored by Amazentis SA.

What drugs are being tested in NCT04160312?

Interventions in NCT04160312: Mitopure™ (Proprietary Urolithin A), Pomegranate Juice.

What condition does NCT04160312 study?

NCT04160312 studies Healthy, Healthy Aging.

Is NCT04160312 still recruiting?

NCT04160312 is currently completed. Last updated 10 April 2020.

Last reviewed 2020-04-10 · How we verify

NCT04160312: NOURISH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mitopure™ (Proprietary Urolithin A) Bioavailability in Healthy Adults

Completed NA Last updated 10 April 2020

What this trial tests

NA trial testing Mitopure™ (Proprietary Urolithin A) in Healthy in 100 participants. Completed in 31 March 2020.

Timeline

8 November 2019

Primary endpoint
29 February 2020

31 March 2020

Quick facts

Lead sponsor	Amazentis SA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	100
Start date	8 November 2019
Primary completion	29 February 2020
Estimated completion	31 March 2020
Sites	1 location across United States

Drugs / interventions tested

Mitopure™ (Proprietary Urolithin A)
Pomegranate Juice

Conditions studied

Healthy — all drugs for Healthy →
Healthy Aging — all drugs for Healthy Aging →

Sponsor

Amazentis SA — full company profile →

Who can join

Adults 18 to 80, any sex, with Healthy or Healthy Aging. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, two-period, crossover, randomized, open labelled study enrolling 100 healthy subjects to evaluate the Urolithin A producer status and to compare bioavailabilty of direct dietary supplementation with Mitopure™ (proprietary Urolithin A) to dietary exposure with pomegranate juice

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Sarcopenia and Muscle Aging: A Brief Overview.
Dao T, Green AE, Kim YA, Bae SJ, et al · · 2020 · cited 156× · PMID 33397034 · DOI 10.3803/enm.2020.405
Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice.
Xia B, Shi XC, Xie BC, Zhu MQ, et al · · 2020 · cited 100× · PMID 32218572 · DOI 10.1371/journal.pbio.3000688
Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population.
Singh A, D'Amico D, Andreux PA, Dunngalvin G, et al · · 2022 · cited 80× · PMID 34117375 · DOI 10.1038/s41430-021-00950-1
Mitophagy and the Brain.
Swerdlow NS, Wilkins HM. · · 2020 · cited 51× · PMID 33352896 · DOI 10.3390/ijms21249661
Youthful and age-related matreotypes predict drugs promoting longevity.
Statzer C, Jongsma E, Liu SX, Dakhovnik A, et al · · 2021 · cited 42× · PMID 34346557 · DOI 10.1111/acel.13441
The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimer's Disease.
Guha S, Johnson GVW, Nehrke K. · · 2020 · cited 40× · PMID 32851560 · DOI 10.1007/s12035-020-02084-0
Mitochondrial Targeted Interventions for Aging.
Liu SZ, Chiao YA, Rabinovitch PS, Marcinek DJ. · · 2024 · cited 8× · PMID 37788882 · DOI 10.1101/cshperspect.a041199
Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges.
Zhang Q, Zhang W, Yuan X, Peng X, et al · · 2025 · cited 4× · PMID 40722629 · DOI 10.3390/biomedicines13071553

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Amazentis SA trials

Trials by the same sponsor.

NCT07517913 — Cerebrospinal Fluid Kinetics of Urolithin A · NA · not yet recruiting
NCT07517874 — Human Skin Safety Testing of 1 Mitopure Topical Products Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volun · NA · not yet recruiting
NCT07517887 — Anti-aging Efficacy Study on One Cosmetic Product Containing Mitopure · NA · not yet recruiting
NCT07517900 — Human Skin Safety Testing of 1 Mitopure Topical Product Using a Clinical Safety in Use Study in Healthy Volunteers · NA · not yet recruiting
NCT07231783 — The Effect of Urolithin A (Mitopure®) Supplementation on Muscle Strength in Healthy Middle-Aged Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04160312 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amazentis SA
Last refreshed: 10 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04160312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing